Gemini Therapeutics Inc. (GMTX) saw an uptrend of 3.09% in the recent trading with $5.68 being its most recent. The current price level -70.24% lower than the highest price of $19.08 marked by the stock while trading over the past 52-weeks, whereas it is 4.22% higher than the lowest price of $5.45 the company dropped to over past 52-weeks. The latest news story on GMTX appeared in Business Wire under the title “Gemini Therapeutics Announces Initial Data From Its Ongoing Phase 2a Study of GEM103 in Patients With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration” on Jun-22-21.
Squeezing the time span to 30 day period shows us the stock is currently trading -53.82% below one month high and is +7.78% above of the lowest during that time. Looking into the simple moving average, Gemini Therapeutics Inc. (GMTX)’s stock stands at a SMA-50 of $10.11 while that of 5-day is reading $5.86.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Currently, the stock has been recommended as Strong Buy by 4 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.20 for the stock.
Gemini Therapeutics Inc. Earnings – What Happened With GMTX
Coming around sales and income figures, publically trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor.
GMTX – Gemini Therapeutics Inc. Stock Earnings Estimates
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 32.03 million. GMTX does have institutional investors; and they hold 72.20% of the stock.
Gemini Therapeutics Inc. – Insider Activity and Holdings
Currently, the stock has been recommended as Strong Buy by 4 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.20 for the stock.
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, current ratio recorded by Gemini Therapeutics Inc. was 2.24 while posting a debt to equity ratio of 0.05.